Great Lakes Advisors LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP

by · The Markets Daily

Great Lakes Advisors LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 61,481 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,089,000.

A number of other large investors have also added to or reduced their stakes in the stock. KBC Group NV acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the transaction, the vice president owned 74,424 shares in the company, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at approximately $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Guggenheim cut their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.83.

Check Out Our Latest Report on ANI Pharmaceuticals

ANI Pharmaceuticals Price Performance

ANIP opened at $78.02 on Thursday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The stock’s 50 day simple moving average is $80.57 and its 200 day simple moving average is $78.94. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 16.81 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

About ANI Pharmaceuticals

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Recommended Stories

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).